Oncternal Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 39.48 million compared to USD 44.17 million a year ago. Basic loss per share from continuing operations was USD 13.43 compared to USD 16.8 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.045 USD | +0.50% | +2.49% | -15.66% |
May. 09 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Oncternal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.66% | 26.64M | |
+65.15% | 62.59B | |
-1.15% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.55% | 19.09B | |
+5.12% | 13.08B | |
+25.47% | 12.26B | |
+28.21% | 12.05B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023